An Open Label Field Study of Anthim (Obiltoxaximab) in Subjects Exposed to B. Anthracis

NCT03088111 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Infection, Bacterial
Anthrax

Interventions

OTHER: Collection of samples
BIOLOGICAL: Obiltoxaximab

Sponsor

Elusys Therapeutics

Collaborators

[object Object]
[object Object]